Ignace Vergote

机构：Gynecologic Oncology Group, European Union, Universitair Ziekenhuis Leuven, The European Academy of Gynaecological Surgery, VIB-KU Leuven Center for Cancer Biology, Catholic University of America, Stanford University, KU Leuven · ORCID：0000-0002-7589-8981

发表论文 1878 篇 · 总被引 92808 次 · h-index 137

代表论文

• Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial (2026 · International Journal of Gynecological Cancer)
• Impact of atypical extra-villous trophoblast foci on the natural history and management of post-molar gestational trophoblastic neoplasia (2026 · International Journal of Gynecological Cancer)
• Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors (2025)
• Data from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors (2025)
• Table S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors (2025)
• Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors (2025)